Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.

TMPRSS2-ERG gene fusions occur in over 50% of prostate cancers, but their impact on clinical outcomes is not well understood. Retention of interstitial genes between TMPRSS2 and ERG has been reported to influence tumor progression in an animal model. In this study, we analyzed the status of TMPRSS2-ERG fusion genes and interstitial genes in tumors from a large cohort of men treated surgically for prostate cancer, associating alterations with biochemical progression. Through whole-genome mate pair sequencing, we mapped and classified rearrangements driving ETS family gene fusions in 133 cases of very low-, low-, intermediate-, and high-risk prostate cancer from radical prostatectomy specimens. TMPRSS2-ERG gene fusions were observed in 44% of cases, and over 90% of these fusions occurred in ERG exons 3 or 4. ERG fusions retaining interstitial sequences occurred more frequently in very low-risk tumors. These tumors also frequently displayed ERG gene fusions involving alternative 5'-partners to TMPRSS2, specifically SLC45A3 and NDRG1 and other ETS family genes, which retained interstitial TMPRSS2/ERG sequences. Lastly, tumors displaying TMPRSS2-ERG fusions that retained interstitial genes were less likely to be associated with biochemical recurrence (P = 0.028). Our results point to more favorable clinical outcomes in patients with ETS family fusion-positive prostate cancers, which retain potential tumor-suppressor genes in the interstitial regions between TMPRSS2 and ERG Identifying these patients at biopsy might improve patient management, particularly with regard to active surveillance. Cancer Res; 77(22); 6157-67. ©2017 AACR.

[1]  A. Atala.  Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer. , 2017, The Journal of urology.

[2]  R. Bronson,et al.  Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression. , 2016, Cancer research.

[3]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[4]  Sarah H. Johnson,et al.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer , 2016, Modern Pathology.

[5]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[6]  B. Trock,et al.  Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. , 2015, European urology.

[7]  J. Cheville,et al.  Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. , 2015, Molecular cell.

[8]  Faraz Hach,et al.  Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.

[9]  B. Johansson,et al.  The emerging complexity of gene fusions in cancer , 2015, Nature Reviews Cancer.

[10]  T. Nikolskaya,et al.  Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors , 2015, Journal of Cancer.

[11]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[12]  Andrew Menzies,et al.  Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.

[13]  B. Vainer,et al.  ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. , 2014, European urology.

[14]  Travis M. Drucker,et al.  BIMA V3: an aligner customized for mate pair library sequencing , 2014, Bioinform..

[15]  A. Evans,et al.  TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair , 2013, Clinical Cancer Research.

[16]  Sarah H. Johnson,et al.  Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. , 2013, Cancer research.

[17]  Sarah H. Johnson,et al.  Mate Pair Sequencing of Whole-Genome-Amplified DNA Following Laser Capture Microdissection of Prostate Cancer , 2012, DNA research : an international journal for rapid publication of reports on genes and genomes.

[18]  David I. Smith,et al.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. , 2012, Blood.

[19]  Jennifer R. Rider,et al.  The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[20]  Katelyn Powell,et al.  TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. , 2012, Journal of cancer science & therapy.

[21]  G. Jenster,et al.  ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer , 2012, Modern Pathology.

[22]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[23]  Peter C. Hollenhorst,et al.  Genomic and biochemical insights into the specificity of ETS transcription factors. , 2011, Annual review of biochemistry.

[24]  Asha A. Nair,et al.  The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. , 2010, Cancer research.

[25]  Martin J. Aryee,et al.  Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.

[26]  M. Rubin,et al.  Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort , 2009, Modern Pathology.

[27]  M. Teixeira,et al.  Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. , 2008, The American journal of surgical pathology.

[28]  J. Cuzick,et al.  Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.

[29]  C. D. Savci-Heijink,et al.  Identification of Prognostic Biomarkers for Prostate Cancer , 2008, Clinical Cancer Research.

[30]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[31]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[32]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[33]  A. Gutierrez-Hartmann,et al.  ETS transcription factors in endocrine systems , 2007, Trends in Endocrinology & Metabolism.

[34]  G. Jenster,et al.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.

[35]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[36]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[37]  Toshiyuki Yamada,et al.  Molecular biology of the Ets family of transcription factors. , 2003, Gene.

[38]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[39]  J. Cheville,et al.  Perineural Invasion and MIB-1 Positivity in Addition to Gleason Score Are Significant Preoperative Predictors of Progression After Radical Retropubic Prostatectomy for Prostate Cancer , 2002, The American journal of surgical pathology.

[40]  A. Chinnaiyan,et al.  Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.

[41]  Inge Jonassen,et al.  ERG upregulation and related ETS transcription factors in prostate cancer. , 2007, International journal of oncology.

[42]  F. Cavalli,et al.  Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. , 2004, Nucleic acids research.